No More Yo-Yo Diets? Novo Nordisk's Game-changing Drug CagriSema Achieves Stunning 22.7% Weight Loss

In a boon for those grappling with obesity or excess weight, CagriSema, an investigational product by pharmaceutical titan Novo Nordisk, has shown unprecedented results in weight reduction. In the company’s REDEFINE 1 trial, CagriSema demonstrated a remarkable 22.7% mean weight loss in adult participants. The trial, the results of which were simultaneously presented at the American Diabetes Association’s 85th Scientific Sessions and published in the New England Journal of Medicine, examined the product’s efficacy as a weight loss intervention for adults who are overweight or have obesity-related medical complications, excluding diabetes. A staggering 97.6% of patients observed a weight loss of 5% or greater, with 60.2%, 40.4% and 23.1% achieving ≥20%, ≥25%, and ≥30% weight loss respectively over 68 weeks. Furthermore, treatment with CagriSema led to a significantly greater weight loss of 22.7% compared to the placebo’s 2.3% when all patients maintained adherence to treatment. This groundbreaking trial also revealed that over half of the participants initially categorised as obese, post-treatment reached a threshold for non-obesity suggesting a significant impact on public health if widely adopted. ‘These results reinforce our confidence in CagriSema’, says Martin Holst Lange, Novo Nordisk’s Executive Vice President. All eyes are now on CagriSema as a potential game-changer in tackling the obesity epidemic.